Principal Investigator: Cliff Watson / Matt Walters
Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Award Date: 5/6/2011
Institution: Centers for Disease Control and Prevention
In order to develop the scientific basis for product standards and evaluate the impact of FDA's regulatory activities on tobacco products, the FDA will measure current ranges for harmful and potentially harmful constituents (HPHCs) in smoke and smokeless tobacco products. Currently, 93 constituents are included in FDA’s established HPHC list. Using the analytical methods established in the project entitled “Method Development for Priority HPHCs in Tobacco Smoke and Smokeless Tobacco Products,” investigators will analyze HPHC levels in 30 common cigarette brands and 15 common smokeless brands in order to establish baseline HPHC levels. Both International Organization for Standardization (ISO) and Health Canada’s Canadian Intense (CI) smoking regimens will be used to measure HPHCs in cigarettes and smokeless tobacco products.